Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX-Erlotinib in Advanced Pancreatic Cancer
NCT00636883Phase 2Terminated
- Sponsor
- Ministry of National Guard Health Affairs
- Start
- Jan 2008
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in pancreatic cancer (PC), sponsored by Ministry of National Guard Health Affairs. Primary endpoint: Response Rate. Started Jan 2008; status: terminated.
02
Drugs
erlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00636883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00636883.